+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-3: Human fetal brain tissue, 293T cells, Hela cells, Primary antibody: P11956(STK26 Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

The STK26 antibody is designed to target serine/threonine kinase 26 (STK26), also known as mammalian STE20-like kinase 4 (MST4), a member of the germinal center kinase III subfamily. STK26 is a ubiquitously expressed protein kinase involved in regulating cell polarity, proliferation, apoptosis, and stress responses. It interacts with signaling pathways such as the ERK and JNK cascades, often through phosphorylation of downstream substrates. STK26 localizes to the Golgi apparatus and plasma membrane, where it participates in maintaining cellular structure and function, particularly in response to oxidative or osmotic stress.

Antibodies against STK26 are widely used in research to study its expression, localization, and mechanistic roles in physiological and pathological contexts. These antibodies (monoclonal or polyclonal) are typically validated for applications like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). STK26 has garnered attention in cancer research due to its dual role in promoting or suppressing tumor growth, depending on the cellular context. For instance, it may inhibit colorectal cancer progression by modulating apoptosis but enhance migration in hepatocellular carcinoma. Dysregulation of STK26 is also linked to inflammatory diseases and metabolic disorders. Researchers utilize STK26 antibodies to explore its potential as a therapeutic target or biomarker, though its complex regulatory networks warrant further investigation.